Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / SABS - SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies

SABS - SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies

SAB Biotherapeutics Inc.
  • SAB Biotherapeutics is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.
  • The Company's Tc Bovine-based DiversitAb platform has presented two PoCs in the past two months.
  • The Company’s development candidates receive support from U.S. government-funded programs.

For further details see:

SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies
Stock Information
Company Name: SAB Biotherapeutics Inc.
Stock Symbol: SABS
Market: NASDAQ
Website: sabbiotherapeutics.com
Menu
SABS SABS Quote SABS Short SABS News SABS Articles SABS Message Board
Get SABS Alerts

News, Short Squeeze, Breakout and More Instantly...